{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:09:25Z","timestamp":1761109765695},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1157\/13098570","type":"journal-article","created":{"date-parts":[[2007,3,19]],"date-time":"2007-03-19T10:39:29Z","timestamp":1174300769000},"page":"98-107","source":"Crossref","is-referenced-by-count":13,"title":["Costes de la toxicidad asociada a los an\u00e1logos de nucle\u00f3sidos inhibidores de la transcriptasa inversa en pacientes con infecci\u00f3n por el VIH-1"],"prefix":"10.1016","volume":"25","author":[{"given":"Josep","family":"Maria Llibre-Codina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"\u00c1ngel Casado-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainel","family":"S\u00e1nchez-de la Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Jes\u00fas P\u00e9rez-El\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Santos-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Miralles-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Mart\u00ednez-Chamorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo-Pedrol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Luisa \u00c1lvarez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Moreno-Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13098570_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/00019053-200119070-00001","article-title":"Highly active antiretroviral therapy: Pharmacoeconomical issues in the management of HIV infection","volume":"19","author":"Sendi","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1157\/13098570_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/jac\/dkh142","article-title":"Costs associated with combination antiretroviral therapy in HIV-infected patients","volume":"53","author":"Yazdanpanah","year":"2004","journal-title":"J Antimicrob Chem"},{"key":"10.1157\/13098570_bib3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1468-1293.2000.00036.x","article-title":"Economic impact of HIV protease inhibitor therapy in the global use of health-care resources","volume":"1","author":"Velasco","year":"2000","journal-title":"HIV Med"},{"key":"10.1157\/13098570_bib4","first-page":"269","article-title":"Cost distribution of highly active antiretroviral therapy","volume":"21","author":"Tornero","year":"2004","journal-title":"An Med Interna"},{"key":"10.1157\/13098570_bib5","first-page":"2411","article-title":"The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001","volume":"18","author":"Beck","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13098570_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00019053-199813030-00003","article-title":"Application of modelling studies","volume":"13","author":"Nuitjen","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1157\/13098570_bib7","series-title":"15th Inth AIDS Conf Bangkok","article-title":"Costs of HIV management: 1995 to 2003","author":"Bernal","year":"2004"},{"key":"10.1157\/13098570_bib8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study","volume":"357","author":"Mart\u00ednez","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13098570_bib9","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1345\/aph.1A199","article-title":"Hyperlipidemia in HIV-positive patients receiving antiretrovirals","volume":"36","author":"Segarra-Newnham","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1157\/13098570_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1468-1293.2005.00269.x","article-title":"Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: A retrospective cohort study","volume":"6","author":"Richter","year":"2005","journal-title":"HIV Medicine"},{"key":"10.1157\/13098570_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0213-9111(00)71427-0","article-title":"La utilizaci\u00f3n de recursos sanitarios en pacientes infectados por el virus de la inmunodeficiencia humana: creaci\u00f3n de una base de datos y obtenci\u00f3n de resultados de costes","volume":"14","author":"Momp\u00f3","year":"2000","journal-title":"Gac Sanit"},{"key":"10.1157\/13098570_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1524-4733.2003.00242.x","article-title":"A checklist for retrospective database studies. Report of the ISPOR task force on retrospective databases","volume":"6","author":"Motheral","year":"2003","journal-title":"Value Health"},{"key":"10.1157\/13098570_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2710.2003.00458.x","article-title":"Use of pharmacoeconomics in prescribing research. Modelling beyond clinical trials","volume":"28","author":"Lang","year":"2003","journal-title":"J Clin Pharm & Ther"},{"key":"10.1157\/13098570_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1157\/13069520","article-title":"Recomendaciones de GESIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004)","volume":"22","author":"Iribarren","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13098570_bib15","unstructured":"Panel on Clinical Practices for Treatment of IV infection convened by the Department of Health and Human Services (DDHHS). Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. April 7, 2005. Disponible en: http:\/\/aidsinfo.nih.gov\/guidelines\/adult\/AA_040705.pdf"},{"key":"10.1157\/13098570_bib16","unstructured":"Casado MA. An\u00e1lisis parciales de evaluaci\u00f3n econ\u00f3mica de medicamentos: descripci\u00f3n de costes, estudios de coste de la enfermedad, an\u00e1lisis coste-consecuencia, an\u00e1lisis de costes. An\u00e1lisis de minimizaci\u00f3n de costes. En: Dom\u00ednguez- Gil A, Soto J, editores. Farmacoeconom\u00eda e investigaci\u00f3n de resultados en la salud: principios y pr\u00e1ctica. 2.\u00aa ed. Real Academia Nacional de Farmacia; 2001. p. 173-208. Disponible en: http:\/\/www.raf.es\/Publicaciones\/Monografias\/monografia10.htm"},{"key":"10.1157\/13098570_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1157\/13059544","article-title":"An\u00e1lisis de costes y resultados en la evaluaci\u00f3n econ\u00f3mica de las intervenciones sanitarias","volume":"122","author":"Prieto","year":"2004","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13098570_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.curtheres.2005.04.002","article-title":"Treatment-limiting toxicities associated with nucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study","volume":"66","author":"Palacios","year":"2005","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1157\/13098570_bib19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/01.aids.0000233574.49220.de","article-title":"Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir","volume":"20","author":"Llibre","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13098570_bib20","unstructured":"Moreno S, Casado MA, Domingo P, Llibre JM, Mart\u00ednez E, Miralles C, et al. Tenofovir DF is associated with decreased HIV-related healthcare costs in HIV-1-infected heavily pre-treated patients with nucleoside reverse transcriptase inhibitors-related toxicity. 10th European AIDS Conference\/ EACS. Dublin, Ireland. 17-20 November 2005."},{"key":"10.1157\/13098570_bib21","first-page":"L48","article-title":"Cost of the NRTI-related toxicities in HIV-1-infected heavily experienced patients","volume":"10","author":"Moreno","year":"2005","journal-title":"Antiviral Therapy"},{"key":"10.1157\/13098570_bib22","unstructured":"AIDS Clinical Trials Group. Table for grading severity of adult adverse experiences. Disponible en: http:\/\/aactg.s-3.com"},{"key":"10.1157\/13098570_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00019053-199508030-00007","article-title":"Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation","volume":"8","author":"Rovira","year":"1995","journal-title":"Pharmacoeconomics"},{"key":"10.1157\/13098570_bib24","series-title":"Base de datos de costes sanitarios","author":"Gisbert","year":"2005"},{"key":"10.1157\/13098570_bib25","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos de Espa\u00f1a. Cat\u00e1logo de Especialidades Farmac\u00e9uticas. Colecci\u00f3n Consejo Plus 2005 (marzo de 2005)."},{"key":"10.1157\/13098570_bib26","unstructured":"Ministerio de Sanidad y Consumo. Real Decreto 2402\/2004, de 30 de diciembre, por el que se desarrolla el art\u00edculo 104 de la Ley 25\/1990, de 20 de diciembre, del Medicamento, para las revisiones coyunturales de precios de especialidades farmac\u00e9uticas y se adoptan medidas adicionales para la contenci\u00f3n del gasto farmac\u00e9utico."},{"key":"10.1157\/13098570_bib27","unstructured":"Ministerio de Sanidad y Consumo. Resoluci\u00f3n de 15 de febrero de 2005, de la Direcci\u00f3n General de Farmacia y Productos Sanitarios, por la que se modifica el anexo del Real Decreto 2402\/2004, de 30 de diciembre, por el que se desarrolla el art\u00edculo 104 de la Ley 25\/1990, de 20 de diciembre, del Medicamento, para las revisiones coyunturales de precios de especialidades farmac\u00e9uticas y se adoptan las medidas adicionales para la contenci\u00f3n del gasto farmac\u00e9utico."},{"key":"10.1157\/13098570_bib28","unstructured":"Ministerio de Trabajo y Asuntos Sociales. Real Decreto 2388\/2004, de 30 de diciembre, estableciendo el Salario M\u00ednimo Interprofesional para 2005."},{"key":"10.1157\/13098570_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1157\/13059336","article-title":"Evaluaci\u00f3n econ\u00f3mica en medicina","volume":"122","author":"Sacrist\u00e1n","year":"2004","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13098570_bib30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00019053-200321090-00002","article-title":"Assessing the economic impact of adverse drug effects","volume":"21","author":"Rodr\u00edguez-Mongui\u00f3","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1157\/13098570_bib31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jama.277.4.301","article-title":"Adverse drug events in hospitalised patients: Excess length of stay, extra costs, and attributable mortality","volume":"277","author":"Classen","year":"1997","journal-title":"JAMA"},{"key":"10.1157\/13098570_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","article-title":"Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: A randomized pilot study","volume":"52","author":"Laguna","year":"2003","journal-title":"J Antimicrob Chem"},{"key":"10.1157\/13098570_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00002030-200003310-00005","article-title":"Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients","volume":"14","author":"D\u2019Arminio Monforte","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13098570_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00019053-199915050-00001","article-title":"Pharmacoeconomic evaluation in the real world","volume":"15","author":"Revicki","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"10.1157\/13098570_bib35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2165\/00019053-200321150-00005","article-title":"Indirect costs in ambulatory patients with HIV\/AIDS in Spain","volume":"21","author":"Oliva","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1157\/13098570_bib36","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ajhp\/61.23.2507","article-title":"Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy","volume":"61","author":"Schiller","year":"2004","journal-title":"Am J Health Syst Pharm"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X07742404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X07742404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T12:39:00Z","timestamp":1556282340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X07742404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0213005X07742404"],"URL":"https:\/\/doi.org\/10.1157\/13098570","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}